Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

2.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.

3.

Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.

4.

Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries

5.

The Effect of Common Steroids on Cancer Treatments.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot